Ionic reported that several autoimmune CAR T cell trials from Novartis and Bristol Myers Squibb were halted due to adverse inflammatory immune related events, including several patient deaths.
Public source
Publisher name
Public post
The news this week that several autoimmune CAR T cell trials (from Novartis and Bristol Myers Squibb) were halted due to adverse inflammatory immune related events, incl…
Company
Ionic
Cytometry Made Easy!
- Industry
- Biotechnology Research
- Location
- Boston, US
- Company size
- 1 employee
About Ionic
We do not see ourselves as traditional consultants but rather as counterparts with complementary expertise. We provide each client with a personalized, custom cytometry investigation based on two-way discourse, enhancing the robustness of the science conducted and bridging the gap between analysis and insight. We begin the process by meeting with clients to understand their project and research goals. If the client has not yet collected data, we build a panel based on the relevant biomarkers, design experiments and protocols to qualify the panel, and advise on appropriate data collection techniques. If the client has already collected data, we will develop an analysis strategy to achieve their goals. Once data becomes available, our custom data analysis reveals its most compelling insights. We meet one-on-one with clients to discuss analyses and assist them in interpreting results and their implications. Our team provides strategies for applying insights to future studies, grant applications, manuscripts, and presentations at scientific and medical conferences.
See moreLatest activity
Latest activity from Ionic
3 signals
Presence & Recognition
Ionic featured Christian Aguilera-Sandoval and Eric Haas in their latest episode of Go With the Flow, A Cytometry Podcast discussing Pratip Chattopadhyay and the future of cytometry.
Research & Knowledge
Ionic published a paper published with City of Hope analyzing differences between CAR T cells in R/R vs. CR1 patients using a 48-parameter CyTOF panel.
Discover more
Similar signals
Similar public activity from other companies.
Legal & Regulatory
RxClarity
RxClarity reports that Autoimmune CAR-T faced a significant safety reset as Novartis and Bristol Myers Squibb paused programmes.
Legal & Regulatory
Cellipont Bioservices
Cellipont Bioservices published a full article on the development of CAR-T therapies for autoimmune and neurological diseases, highlighting patient safety and clinical trials.
Legal & Regulatory
Boston Children's Hospital
Boston Children's Hospital noted that Novartis paused eight autoimmune and neurology trials of its CD19 CAR-T rap-cel on August 24 after three deaths from immune effector cell-associated hemophagocytic syndrome (IEC-HS).
Legal & Regulatory
ViroCell Biologics
ViroCell Biologics announced the new trial using a B7H3-targeted CAR-T to treat children with relapsed and refractory extracranial solid cancers funded by Cancer Research UK, Stand Up To Cancer, and LifeArc.
Legal & Regulatory
Kali Therapeutics